Previous 10 | Next 10 |
2023-12-29 01:25:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-12-11 14:27:17 ET Summary Verve Therapeutics, Inc. released positive interim data from its phase 1b heart-1 study using VERVE-101 for treating HeFH patients; LDL-C reduced by as much as 55% after a single dose. IND clearance for VERVE-101 in the U.S. opens up the inclusion of...
2023-12-11 11:57:44 ET Summary Verve Therapeutics is a biotechnology company focused on developing single-course gene editing medicines for cardiovascular disease (CVD), particularly atherosclerotic cardiovascular disease (ASCVD). The company has advanced its first cardiovascular ...
BOSTON, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc. (Nasdaq: VERV), a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the closing of its previously announced underwritten...
2023-11-30 13:19:51 ET Summary Verve Therapeutics is focused on developing in vivo gene editing therapies for cardiovascular disease. The company aims to disrupt the chronic care model for CVD by targeting genes related to atherosclerotic cardiovascular disease. Verve's interi...
2023-11-29 07:30:19 ET More on Verve Therapeutics Verve's New Beat: CMO Onboard, Catalysts Ahead, But We're Dancing Solo For Now Cracking The Cholesterol Code: Verve's High-Stakes Bet Verve Therapeutics intends to raise cash through public offering Verve fall...
BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc. (Nasdaq: VERV), a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the pricing of an underwritten public offering of 12...
2023-11-28 16:08:20 ET More on Verve Therapeutics Verve's New Beat: CMO Onboard, Catalysts Ahead, But We're Dancing Solo For Now Cracking The Cholesterol Code: Verve's High-Stakes Bet Verve falls after early-stage data for lead asset Verve shares surge to thr...
BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc. (Nasdaq: VERV), a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that it has commenced an underwritten public offerin...
2023-11-21 15:13:40 ET More on Beam, CRISPR, etc. Intellia: Soon-To-Be Enrollment Completion Brings About Catalysts In 2024 Editas Medicine, Inc. (EDIT) Presents at Stifel 2023 Healthcare Conference (Transcript) Beam Therapeutics: Sale Of Rights To Verve's In Vivo Ca...
News, Short Squeeze, Breakout and More Instantly...
Verve Therapeutics Inc. Company Name:
VERV Stock Symbol:
NASDAQ Market:
Verve Therapeutics Inc. Website:
2024-07-08 07:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its boar...
2024-06-15 11:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...